Keratosis, Actinic Clinical Trial
— AKtiveOfficial title:
A Phase 4, Multi-centre, Randomized, Evaluator-blinded, Active-controlled Study to Determine the Incidence of Squamous Cell Carcinoma and Evaluate the Long-term Safety of Tirbanibulin 10 mg/g Ointment and Diclofenac Sodium 3% Gel for the Treatment of Adult Patients With Actinic Keratosis on the Face or Scalp
Verified date | June 2024 |
Source | Almirall, S.A. |
Contact | Victor Castellano |
Phone | +34932746671 |
gco[@]almirall.com | |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of the study is to evaluate the incidence of biopsy confirmed invasive squamous cell carcinoma (SCC) in the selected treatment field (TF) after administration of topical tirbanibulin 10 milligram (mg)/gram (g) ointment or diclofenac sodium 3 percent (%) gel over the 3-year study period.
Status | Recruiting |
Enrollment | 450 |
Est. completion date | March 2027 |
Est. primary completion date | March 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - A treatment field (TF) on the face or scalp (excluding lips, eyelids, ears, and inside the nostrils), that: a) is a contiguous area measuring 25 cm^2, b) contains 2 to 8 clinically typical, visible, and discrete actinic keratosis (AK) lesions, and c) has an overall clinical picture that is consistent with Olsen grade 1 - If a women of child-bearing potential (WOCBP), that is, fertile, defined as a female in the life period from menarche and until becoming post-menopausal (no menses for 12 months without an alternative medical cause) or permanently sterile (with hysterectomy, bilateral salpingectomy or bilateral oophorectomy at least 3 months prior to Screening), she must: a) Have a negative urine pregnancy test using a highly sensitive method at screening and on Day 1 prior to treatment administration. b) Be using effective methods of birth control. c) Agree to have pregnancy tests while in the study and at the end of the study - Participants should be willing to avoid sunlight or ultraviolet (UV) light exposure, including the use of tanning beds, to the face or scalp during the study - Participants should have the ability to understand the purpose and risks of the study, willingness and ability to comply with the protocol, and provide written informed consent in accordance with institutional and regulatory guidelines Exclusion Criteria: - The location of the TF is: a) on any location other than the face or scalp. b) within 5 centimeters (cm) of an incompletely healed wound. c) Within 10 cm of a suspected basal cell carcinoma (BCC) or other neoplasm. d) on the lips, eyelids, ears, or inside the nostrils, periorbital, perioral, or the skin surrounding the nostrils - Presence in the TF of: a) clinically atypical and/or rapidly changing AK lesions b) hyperkeratotic or hypertrophic lesions, recalcitrant disease (had cryosurgery on 2 previous occasions), and/or cutaneous horn. c) confluent AK lesions (that is, non-discrete lesions, as per inclusion criterion 2). d) Persisting AK lesions at the screening visit following topical treatment with diclofenac sodium 3 percent (%) gel - History of any malignant skin tumour in the TF or history of skin tumour in any region of the body which has metastasized or in which metastasis within the study period is likely - History of any malignant tumour with systemic antitumor treatment (including radiotherapy) within 12 weeks prior to the Screening Visit or systemic antitumor treatment is expected while on the study - Immunocompromised participants, including participants with a history of chronic systemic lymphoma or chronic myeloid leukaemia, or organ transplant recipients |
Country | Name | City | State |
---|---|---|---|
France | Almirall Investigation Site 102 | Lille | |
France | Almirall Investigation Site 103 | Marseille | |
France | Almirall Investigation Site 104 | Nice | |
France | Almirall Investigational Site 106 | Paris | |
France | Almirall Investigational Site 105 | Rouen | |
France | Almirall Investigational Site 101 | Saint-Priest-en-Jarez | |
Germany | Almirall Investigational Site 205 | Augsburg | |
Germany | Almirall Investigation Site 201 | Bochum | |
Germany | Almirall Investigational Site 208 | Detmold | |
Germany | Almirall Investigational Site 210 | Dresden | |
Germany | Almirall Investigational Site 204 | Erlangen | |
Germany | Almirall Investigational Site 206 | Hamburg | |
Germany | Almirall Investigational Site 207 | Marburg | |
Germany | Almirall Investigational Site 209 | Merzig | |
Germany | Almirall Investigation Site 202 | Recklinghausen | |
Italy | Almirall Investigational Site 309 | Arezzo | |
Italy | Almirall Investigational Site 302 | Brescia | |
Italy | Almirall Investigational Site 304 | Genova | |
Italy | Almirall Investigational Site 308 | Modena | |
Italy | Almirall Investigational Site 301 | Napoli | |
Italy | Almirall Investigational Site 303 | Reggio Emilia | |
Italy | Almirall Investigational Site 305 | Roma | |
Italy | Almirall Investigational Site 306 | Roma | |
Italy | Almirall Investigational Site 307 | Roma | |
Italy | Almirall Investigational Site 310 | Rozzano | |
Poland | Almirall Investigational Site 27 | Kraków | |
Poland | Almirall Investigational Site 403 | Lublin | |
Poland | Almirall Investigational Site 26 | Ostrowiec Swietokrzyski | |
Poland | Almirall Investigational Site 408 | Rzeszów | |
Poland | Almirall Investigational Site 407 | Warsaw | |
Poland | Almirall Investigational Site 401 | Wroclaw | |
Poland | Almirall Investigational Site 402 | Wroclaw | |
Spain | Almirall Investigational Site 502 | Barcelona | |
Spain | Almirall Investigational Site 508 | Barcelona | |
Spain | Almirall Investigational Site 507 | Granada | |
Spain | Almirall Investigational Site 509 | Granada | |
Spain | Almirall Investigational Site 503 | Madrid | |
Spain | Almirall Investigational Site 504 | Salamanca | |
Spain | Almirall Investigational Site 505 | Sevilla | |
Spain | Almirall Investigational Site 506 | Valence | |
Spain | Almirall Investigational Site 501 | Zaragoza | |
United Kingdom | Almirall Investigational Site 709 | Cardiff | |
United Kingdom | Almirall Investigational Site 703 | London | |
United Kingdom | Almirall Investigational Site 708 | Oxford | |
United Kingdom | Almirall Investigational Site 704 | Poole | |
United Kingdom | Almirall Investigational Site 701 | Salford | |
United Kingdom | Almirall Investigational Site 706 | Weston-super-Mare |
Lead Sponsor | Collaborator |
---|---|
Almirall, S.A. |
France, Germany, Italy, Poland, Spain, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of Participants with Histologically Confirmed Invasive Squamous Cell Carcinoma (SCC) in the Treatment Field (TF) | Percentage of participants with histologically confirmed invasive SCC in the TF will be reported as assessed by dermoscopy. | Up to 3 years | |
Secondary | Number of Participants With Adverse Events (AEs) | An Adverse Event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered an Investigational Product. An AE does not necessarily have a causal relationship with the medicinal product. | Up to 3 years | |
Secondary | Number of Participants With Serious Adverse Events (SAEs) | A Serious Adverse Event (SAE) is defined as any untoward medical occurrence that at any dose, resulted in death, was life-threatening (i.e, the participant was at immediate risk of death from the AE as it occurred; this did not include an event that, had it occurred in a more severe form or was allowed to continue, might have caused death), required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect (in the child of a participant who was exposed to the study drug). | Up to 3 years | |
Secondary | Percentage of Participants With any Other Skin Cancer (Other Than SCC) in the TF | Percentage of participants with any other skin cancer (other than SCC) in the TF will be reported. | Up to 3 years | |
Secondary | Time to Occurrence of Invasive SCC From Baseline in the TF | Time to occurrence of invasive SCC from baseline in the TF will be reported. | Up to 3 years | |
Secondary | Percentage of Participants Requiring Rescue Treatment After 1 Treatment Course | Percentage of participants requiring rescue treatment after 1 treatment course will be reported. | Up to 3 years | |
Secondary | Percentage of Participants Requiring Rescue Treatment at Any Time During the Study | Percentage of participants requiring rescue treatment at any time during the study will be reported. | Up to 3 years | |
Secondary | Percentage of Participants With no Lesions After Treatment of the First Recurrence With Tirbanibulin During the First 52 Weeks | Percentage of participants with no lesions after treatment of the first recurrence with tirbanibulin during the first 52 weeks will be reported. | Up to Week 52 | |
Secondary | Number of Participants With Vital Signs Abnormalities | Number of participants with vital signs (including measurement of heart rate, respiratory rate, systolic and diastolic blood pressure and tympanic temperature) will be reported. | Up to 3 years | |
Secondary | Number of Participants With Physical Examination Abnormalities | Number of participants with physical examination abnormalities (height, weight and an assessment of head, eyes, ears, nose and throat, integumentary/dermatological, gastrointestinal, cardiovascular, respiratory, musculoskeletal, and neurological systems) will be reported. | Up to 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03076892 -
Evaluation of Non-inferiority and Tolerability of the Device PHOS-ISTOS
|
N/A | |
Terminated |
NCT03076918 -
Evaluating the Device FLEXITHERALIGHT Compared to the Conventional Photodynamic Therapy
|
N/A | |
Completed |
NCT05356572 -
A Pre-market Study to Evaluate the Performance and Safety of a Skin Preparation Device for Removal of Dry Crusty Skin
|
N/A | |
Completed |
NCT02594644 -
The Use of Microneedles to Expedite Treatment Time in Photodynamic Therapy
|
N/A | |
Active, not recruiting |
NCT02281682 -
IM Versus 5-FU Versus IMI Versus MAL-PDT in Treatment of Actinic Keratosis
|
Phase 4 | |
Completed |
NCT01458587 -
Levulan PDT Versus Vehicle for Extremity Actinic Keratoses (AK)
|
Phase 2 | |
Completed |
NCT05260073 -
Patient and Clinician Reported Outcomes for Tirbanibulin Effectiveness and Safety in Actinic Keratosis
|
||
Active, not recruiting |
NCT06014697 -
OCT and Invasion in Cutaneous Skin Lesions
|
||
Completed |
NCT05279131 -
A Study to Evaluate the Safety and Tolerability of Tirbanibulin Ointment 1% in Adult Participants With Actinic Keratosis
|
Phase 3 | |
Completed |
NCT05481073 -
UV Sensor in Patients With Actinic Keratosis
|
||
Completed |
NCT03697590 -
Photodynamic Therapy of Actinic Keratosis of the Face and Scalp With and Without Prior Curettage
|
Phase 4 | |
Withdrawn |
NCT02813902 -
A Trial of Polypodium Leucotomos in Preventing Skin Cancer and Its Precursors
|
Phase 1 | |
Recruiting |
NCT05636800 -
Microwave Treatment for Actinic Keratosis
|
N/A | |
Completed |
NCT02628236 -
Maximal Use Systemic Exposure Study of Levulan Kerastick (MUSE 2)
|
Phase 2 | |
Recruiting |
NCT06135415 -
A Study to Evaluate the Efficacy and Safety of Tirbanibulin Ointment in Adult Participants With Actinic Keratosis
|
Phase 3 | |
Completed |
NCT02644187 -
Pain Relief During Photodynamic Therapy for Actinic Keratoses With a New Irradiation Protocol
|
N/A | |
Completed |
NCT02281136 -
MUSE Study of Levulan Kerastick
|
Phase 2 | |
Completed |
NCT05060237 -
Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp
|
Phase 1 | |
Terminated |
NCT04269395 -
A Study to Assess Recurrence of Actinic Keratosis in Participants Treated With Methyl Aminolevulinate Hydrochloride Cream or Vehicle Cream Who Achieved Complete Response to Treated Lesions in Earlier Study
|
Phase 3 |